Peer-influenced content. Sources you trust. No registration required. This is HCN.

ASCO Educational BookIntroducing Checkpoint Inhibitors Into the Curative Setting of Head and Neck Cancers: Lessons Learned, Future Considerations

Despite the array of intensive treatment approaches, local control and overall survival rates in patients with advanced-stage disease remain low (approximately 40%–50% at 5 years). This review discusses recent studies integrating ICIs into definitive treatment regimens.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form